Mural Oncology PLC (MURA) Actualités

Form 8-K - Current report

Mural Oncology Announces Plans to Explore Strategic Alternatives

Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3...

Form 8-K - Current report

Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer

Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones

Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference

WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a...

Form 8-K - Current report

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2...